Investigation of exomic variants associated with overall survival in ovarian cancer

SJ Winham; A Pirie; YA Chen; MC Larson; ZC Fogarty; MA Earp; H Anton-Culver; EV Bandera; D Cramer; JA Doherty; MT Goodman; J Gronwald; BY Karlan; SK Kjaer; DA Levine; U Menon; RB Ness; CL Pearce; T Pejovic; MA Rossing; N Wentzensen; YT Bean; M Bisogna; LA Brinton; ME Carney; JM Cunningham; C Cybulski; A DeFazio; EM Dicks; RP Edwards; SA Gayther; A Gentry-Maharaj; M Gore; ES Iversen; A Jensen; SE Johnatty; J Lester; HY Lin; J Lissowska; J Lubinski; J Menkiszak; F Modugno; KB Moysich; I Orlow; MC Pike; SJ Ramus; H Song; KL Terry; PJ Thompson; JP Tyrer; DJ Van Den Berg; RA Vierkant; AF Vitonis; C Walsh; LR Wilkens; AH Wu; H Yang; A Ziogas; A Berchuck; G Chenevix-Trench; JM Schildkraut; J Permuth-Wey; CM Phelan; PDP Pharoah; BL Fridley; TA Sellers; EL Goode; D Bowtell; D Gertig; A Green; P Webb; P Parsons; N Hayward; D Whiteman

Journal article

Investigation of exomic variants associated with overall survival in ovarian cancer

SJ Winham, A Pirie, YA Chen, MC Larson, ZC Fogarty, MA Earp, H Anton-Culver, EV Bandera, D Cramer, JA Doherty, MT Goodman, J Gronwald, BY Karlan, SK Kjaer, DA Levine, U Menon, RB Ness, CL Pearce, T Pejovic, MA Rossing Show all

Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2016

DOI: 10.1158/1055-9965.EPI-15-0240

Abstract

Background: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC). Methods: The primary patient set (Set 1) included 14 independentEOCstudies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individuall..

View full abstract

University of Melbourne Researchers

Dorota Gertig Author

Grants

Awarded by University of Sydney

Funding Acknowledgements

This work was supported by grants from the NIH Office of Research on Women's Health (Building Interdisciplinary Careers in Women's Health award K12HD065987; to S.J. Winham) and Genetic Associations and Mechanisms in Oncology (GAME-ON), an NCI Cancer Post-GWAS Initiative (U19-CA148112; to T.A. Sellers). G. Chenevix-Trench is supported by Fellowships from NHMRC. A. deFazio is supported by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney West Translational Cancer Research Centre. C.M. Phelan is funded in part by NIH R01 CA-149429. A. Pirie is funding in part by a Medical Research Council Studentship. A. Gentry-Maharaj is supported by Eve Appeal and the Oak Foundation. In addition, the individual study sites were supported by: AUS: U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729; to G. Chenevix-Trench), National Health & Medical Research Council of Australia (199600 and 400281; to G. Chenevix-Trench), Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania, Cancer Foundation of Western Australia. DOV: Funding for this study was provided by U19-CA148112 (to T. Sellers); HAW: NIH (R01-CA58598, N01-CN-55424, and N01-PC-67001; to M.T. Goodman); HOP: US Army Medical Research and Material Command DAMD17-02-1-0669 (to F. Modugno); NCI K07-CA080668, R01-CA95023, R01-CA126841 (to F. Modugno); P50-CA159981 (to F. Modugno); NIH/National Center for Research Resources/General Clinical Research Center grant M01-RR000056 (to F. Modugno); LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN; to B.Y. Karlan) and the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000124 (to B. Y. Karlan); MAL: funding for this study was provided by research grant R01-CA61107 from the NCI, Bethesda, MD (to S.K. Kjaer and A. Jensen); research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark (to S.K. Kjaer and A. Jensen); and the Mermaid I project (to S.K. Kjaer and A. Jenesn); MAC and MAY: NIH (R01-CA122443, P30-CA15083, P50-CA136393; to E.L. Goode); NCO: Department of Defense (DAMD17-02-1-0666; to J.M. Schildkraut); NEC: NIH R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802 (to K.L. Terry); NJO: NCI (NIH-K07 CA095666, NIH-K22-CA138563, and P30-CA072720; to E.V. Bandera) and the Cancer Institute of New Jersey (to E.V. Bandera); ORE: OHSU Foundation (to T. Pejovic); POC: Pomeranian Medical University (to J. Gronwald); RMH: Cancer Research UK (no grant number is available), Royal Marsden Hospital (to P.D. Pharoah); SEA: Cancer Research UK (C490/A10119 C490/A10124; to P.D. Pharoah); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, SEARCH team, Craig Luccarini, Caroline Baynes, Don Conroy; UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre (to U. Menon and S.A. Gayther). USC: P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, N01-CN025403 (to M.C. Pike), R03-CA113148, R03-CA115195 (to C.L. Pearce), and California Cancer Research Program (0001389V-20170, 2II0200; to A. Wu); POL: Intramural Research Program of the NCI.